ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00492388
Recruitment Status : Terminated (Business decision not to continue development)
First Posted : June 27, 2007
Last Update Posted : January 11, 2012
Sponsor:
Information provided by (Responsible Party):
Hospira, now a wholly owned subsidiary of Pfizer

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : August 2011
  Actual Study Completion Date : August 2011